Oxnard-based Cal Amp, which makes products for the wireless sector, beat analyst estimates on Oct. 1 when it reported second quarter 2016 results. Cal Amp posted earnings of 27 cents per share, beating analyst estimates of 26 cents per share. Analysts expected Cal Amp’s revenues to be around $68 million, but the company beat those Read More →
One of the world’s most expensive cancer drugs got conditional approval from European regulators on Sept. 25. Europeans granted Thousand Oaks-based Amgen conditional approval of its rare blood cancer drug Blincyto and gave a positive evaluation of Amgen’s multiple-myeloma drug Kyprolis. Blincyto is an immunotherapy that is designed to treat a rare form of leukemia Read More →
Sientra’s shares nosedived more than 52 percent on Sept. 24 and several law firms around the country announced on Sept. 25 investigations into possible violations of federal securities laws. On Sept. 23, the Goleta-based breast implant manufacturer sold 3 million new shares in a public offering. The offering raised $66 million for the company before Read More →
An experimental multiple myeloma treatment using Amgen’s Kyprolis will get an expedited review from the U.S. Food and Drug Administration. The FDA said it will use an expedited review process to review a multiple-myeloma treatment using Kyprolis and the genric drug dexamethasone. On July 23, Amgen submitted additional data to the FDA which compared this Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Thousand Oaks-based biopharmaceutical giant Amgen bought a Netherlands-based company and partnered with a Monrovia-based company in an effort to fend off competitors. Amgen announced Sept. 16 that it will buy Dezima, a biotech company focused on developing new treatments for dyslipidemia, a disease where a person has an abnormal amount of lipids in their blood. Read More →
Goleta-based breast implant manufacturer Sientra updated documents for its second public offering on Sept. 14 and it will offer 525,000 new shares. On Sept. 3, Sientra filed documents with the Securities and Exchange Commission for a new public offering. At the time, the documents did not list the amount of shares Sientra planned to offer. Read More →
